Mephedrone Impact on Matrix Metalloproteinases Activity - Do they Influence the Memory Processes?
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: The use of drugs of addiction, as mephedrone, is associated with functional neuronal disorders due to remodeling of the nervous tissue. Key enzymes in remodeling are extracellular matrix (ECM) proteases like matrix metalloproteases (MMPs). Recently, MMPs have been of great interest as some studies point to a fact that the alterations in structural remodeling of synaptic connections modify learning-dependent changes, which remain active even after a prolonged period of abstinence. This entails a continuous development of dependence.
OBJECTIVES: The aim of the study was to determine the influence of subchronic exposure to three different doses of mephedrone on the activity of MMP-2 and 9 in hippocampus and prefrontal cortex and how this was correlated with memory processes in mice.
METHODS: The homogenates of hippocampus and cortex were assayed for MMP-2 and MMP-9 activity by gelatin zymography. Memory consolidation processes were evaluated in the passive avoidance (PA) test.
RESULTS: The study confirmed the dose-dependent increase in activity of MMP-2 and -9 exerted by subchronic administration of mephedrone. Moreover, the highest dose of mephedrone attenuated consolidation of memory and learning processes.
CONCLUSIONS: We could hypothesize that inhibition of MMPs can be considered as a therapeutic option for the treatment of addictive behaviors associated with cognitive processes. Moreover, further studies are required to find out if elevated activities of MMPs contribute to brain damage or recovery from brain damage caused directly by mephedrone.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Current molecular pharmacology - 12(2019), 2 vom: 22., Seite 115-121 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boguszewska-Czubara, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.08.2019 Date Revised 16.08.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1874467212666190114154307 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM292764812 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM292764812 | ||
| 003 | DE-627 | ||
| 005 | 20231225073833.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1874467212666190114154307 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0975.xml |
| 035 | |a (DE-627)NLM292764812 | ||
| 035 | |a (NLM)30648530 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boguszewska-Czubara, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mephedrone Impact on Matrix Metalloproteinases Activity - Do they Influence the Memory Processes? |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2019 | ||
| 500 | |a Date Revised 16.08.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: The use of drugs of addiction, as mephedrone, is associated with functional neuronal disorders due to remodeling of the nervous tissue. Key enzymes in remodeling are extracellular matrix (ECM) proteases like matrix metalloproteases (MMPs). Recently, MMPs have been of great interest as some studies point to a fact that the alterations in structural remodeling of synaptic connections modify learning-dependent changes, which remain active even after a prolonged period of abstinence. This entails a continuous development of dependence | ||
| 520 | |a OBJECTIVES: The aim of the study was to determine the influence of subchronic exposure to three different doses of mephedrone on the activity of MMP-2 and 9 in hippocampus and prefrontal cortex and how this was correlated with memory processes in mice | ||
| 520 | |a METHODS: The homogenates of hippocampus and cortex were assayed for MMP-2 and MMP-9 activity by gelatin zymography. Memory consolidation processes were evaluated in the passive avoidance (PA) test | ||
| 520 | |a RESULTS: The study confirmed the dose-dependent increase in activity of MMP-2 and -9 exerted by subchronic administration of mephedrone. Moreover, the highest dose of mephedrone attenuated consolidation of memory and learning processes | ||
| 520 | |a CONCLUSIONS: We could hypothesize that inhibition of MMPs can be considered as a therapeutic option for the treatment of addictive behaviors associated with cognitive processes. Moreover, further studies are required to find out if elevated activities of MMPs contribute to brain damage or recovery from brain damage caused directly by mephedrone | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Mephedrone | |
| 650 | 4 | |a cognitive processes | |
| 650 | 4 | |a hippocampus | |
| 650 | 4 | |a matrix metalloproteinases | |
| 650 | 4 | |a memory | |
| 650 | 4 | |a mice | |
| 650 | 4 | |a prefrontal cortex. | |
| 650 | 7 | |a Methamphetamine |2 NLM | |
| 650 | 7 | |a 44RAL3456C |2 NLM | |
| 650 | 7 | |a mephedrone |2 NLM | |
| 650 | 7 | |a 8BA8T27317 |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.24 |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase 9 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.35 |2 NLM | |
| 700 | 1 | |a Kurzepa, Jacek |e verfasserin |4 aut | |
| 700 | 1 | |a Biała, Grażyna |e verfasserin |4 aut | |
| 700 | 1 | |a Kaszubska, Katarzyna |e verfasserin |4 aut | |
| 700 | 1 | |a Grot, Karolina |e verfasserin |4 aut | |
| 700 | 1 | |a Tarkowski, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Kowalczyk, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Silvestro, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Faggio, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Budzyńska, Barbara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current molecular pharmacology |d 2008 |g 12(2019), 2 vom: 22., Seite 115-121 |w (DE-627)NLM185149499 |x 1874-4702 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2019 |g number:2 |g day:22 |g pages:115-121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1874467212666190114154307 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2019 |e 2 |b 22 |h 115-121 | ||